| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 实验模型供应(元) | 479,733.00 | 907,115.00 | 226,740,000.00 | 4,064,419.68 | 85,336,949.68 |
| 药物非临床研究服务(元) | 639,077,149.16 | 1,917,486,560.57 | 810,131,119.36 | 2,308,999,190.69 | 977,772,180.62 |
| 临床服务及其他(元) | - | - | 39,653,089.57 | - | 31,332,001.32 |
| 分部间抵销(元) | - | - | -227,167,664.82 | - | -82,363,843.44 |
| 药物临床前研究服务(元) | 29,018,328.98 | 99,940,096.24 | - | 63,423,186.73 | - |
| 营业成本(元) | |||||
| 实验模型供应(元) | 296,720.87 | 785,126.79 | 217,391,878.69 | 2,598,645.11 | 82,380,229.85 |
| 药物非临床研究服务(元) | 486,022,440.88 | 1,357,812,052.43 | 566,655,173.01 | 1,311,110,280.16 | 544,462,657.71 |
| 临床服务及其他(元) | - | - | 29,633,080.64 | - | 21,511,948.02 |
| 分部间抵销(元) | - | - | -222,256,695.56 | - | -84,845,121.18 |
| 药物临床前研究服务(元) | 21,616,097.67 | 85,963,055.14 | - | 49,992,137.54 | - |
| 毛利(元) | |||||
| 实验模型供应(元) | 183,012.13 | 121,988.21 | 9,348,121.31 | 1,465,774.57 | 2,956,719.83 |
| 药物非临床研究服务(元) | 153,054,708.28 | 559,674,508.14 | 243,475,946.35 | 997,888,910.53 | 433,309,522.91 |
| 临床服务及其他(元) | - | - | 10,020,008.93 | - | 9,820,053.30 |
| 分部间抵销(元) | - | - | -4,910,969.26 | - | 2,481,277.74 |
| 药物临床前研究服务(元) | 7,402,231.31 | 13,977,041.10 | - | 13,431,049.19 | - |
| 毛利率(%) | |||||
| 实验模型供应(%) | 38.15 | 13.45 | 4.12 | 36.06 | 3.46 |
| 药物非临床研究服务(%) | 23.95 | 29.19 | 30.05 | 43.22 | 44.32 |
| 临床服务及其他(%) | - | - | 25.27 | - | 31.34 |
| 分部间抵销(%) | - | - | 2.16 | - | -3.01 |
| 药物临床前研究服务(%) | 25.51 | 13.99 | - | 21.18 | - |
| 收入构成(%) | |||||
| 实验模型供应(%) | 0.07 | 0.04 | 26.70 | 0.17 | 8.43 |
| 药物非临床研究服务(%) | 95.59 | 95.00 | 95.38 | 97.16 | 96.61 |
| 临床服务及其他(%) | - | - | 4.67 | - | 3.10 |
| 分部间抵销(%) | - | - | -26.75 | - | -8.14 |
| 药物临床前研究服务(%) | 4.34 | 4.95 | - | 2.67 | - |
| 毛利构成(%) | |||||
| 实验模型供应(%) | 0.11 | 0.02 | 3.62 | 0.14 | 0.66 |
| 药物非临床研究服务(%) | 95.28 | 97.54 | 94.39 | 98.53 | 96.60 |
| 临床服务及其他(%) | - | - | 3.88 | - | 2.19 |
| 分部间抵销(%) | - | - | -1.90 | - | 0.55 |
| 药物临床前研究服务(%) | 4.61 | 2.44 | - | 1.33 | - |